Rapt, 3M, D.R. Horton
On this episode of Stock Movers:- GSK (GSK) agreed to buy Rapt Therapeutics (RAPT), a US-based biotech developing treatments for patients with inflammatory and immunologic diseases, in a deal valued at $2.2 billion. The UK drug company will pay $58 a share, equivalent to an equity value of $2.2 billion, according to a statement Tuesday. The price represents a premium of 65% compared with Rapt Therapeutics’ closing price of $35.10 on Monday.- 3M (MMM) expects profit and sales to expand this year, signaling the company’s push to prioritize higher-growth markets and accelerate the…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.